Renvela Related Published Studies
Well-designed clinical trials related to Renvela (Sevelamer)
Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer
hydrochloride as a phosphate binder in haemodialysis patients: a pilot study. [2012]
Comparison of Calcium Acetate and Sevelamer on Vascular Function and Fibroblast Growth Factor 23 in CKD Patients: A Randomized Clinical Trial. [2011.11.30]
Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study. [2011.05]
The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. [2011.05]
Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. [2011.03]
Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial. [2011.02.02]
Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study. [2011]
Effect of sevelamer hydrochloride exposure on carotid intima media thickness in hemodialysis patients. [2011]
Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3-4. [2010.12]
Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. [2010.11]
Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. [2010.06.07]
Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia? [2010.04]
A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. [2010.02]
Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data. [2009.12]
A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. [2009.12]
Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. [2009.10]
Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols. [2009.07]
Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. [2009.01]
Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients on sevelamer hydrochloride: which dialysate calcium concentration to use? [2009]
Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function. [2008.09]
A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. [2008.06]
Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis. [2008.04]
A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) Randomized Trial Using Claims Data. [2008.03]
Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. [2008.02]
Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. [2008.01]
Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. [2008.01]
Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. [2008]
A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. [2007.12]
Sevelamer treatment strategy in peritoneal dialysis patients: conventional dose does not make best use of resources. [2007.11]
Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. [2007.11]
Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients. [2007.06]
Well-designed clinical trials possibly related to Renvela (Sevelamer)
A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticum. [2011.08]
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. [2011.01]
Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. [2011]
A randomized controlled trial of oral phosphate binders in the treatment of
pseudoxanthoma elasticum. [2011]
Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. [2010.12]
Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? [2010.02]
Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. [2009.12]
Vascular calcification and QT interval in incident hemodialysis patients. [2009.11]
Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. [2009.10]
[Chronic kidney disease (CKD) and bone. Control of CKD-MBD from the viewpoint of the medical cost] [2009.04]
Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study. [2008.12]
Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison results. [2008.10]
K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. [2008.03]
Lanthanum Carbonate Effectively Controls Serum Phosphate Without Affecting Serum Calcium Levels in Patients Undergoing Hemodialysis. [2008.02]
The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)-2 study. [2008.01]
Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study. [2008]
Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. [2007.11]
Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. [2007.03]
Other research related to Renvela (Sevelamer)
Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer
hydrochloride in hemodialysis patients. [2012]
Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride. [2011.11]
Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: Results from the French ARNOS study. [2011.10]
Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. [2011.06.24]
Sevelamer use and incidence of peritonitis in peritoneal dialysis. [2011.04]
Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients. [2011.02]
Reduction of hyperphosphatemia is related with the reduction of C-reactive protein in dialysis patients. Study in sevelamer-resistant dialysis patients treated with chitosan chewing gum as salivary phosphate binder. [2011]
Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the
treatment of hyperphosphatemia in patients with end-stage renal disease: a US
payer perspective. [2011]
Evaluating the effects of sevelamer carbonate on cardiovascular structure and
function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised
controlled trial. [2011]
[Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality]. [2010.11]
Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V). [2010.11]
Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients. [2010.09]
Effect of Sevelamer Hydrochloride Exposure on Carotid Intima Media Thickness in Hemodialysis Patients. [2010.08.06]
Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer? [2010.03.25]
The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research. [2010.01]
Ten-year experience with sevelamer and calcium salts as phosphate binders. [2010.01]
Sevelamer carbonate reduces inflammation and endotoxemia in an animal model of uremia. [2010]
[Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients:
effects on vascular calcification and mortality]. [Article in Japanese] [2010]
Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis
patients. [2010]
Does concomitant administration of sevelamer and calcium carbonate modify the
control of phosphatemia? [2010]
A randomized, parallel, open-label study to compare once-daily sevelamer
carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing
in CKD patients on hemodialysis. [2010]
Short-term efficacy of sevelamer versus calcium acetate in patients with chronic
kidney disease stage 3-4. [2010]
Other possibly related research studies
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. [2010.09.22]
Fibroblast Growth Factor 23 in Hemodialysis Patients: Effects of Phosphate Binder, Calcitriol and Calcium Concentration in the Dialysate. [2010.08.04]
[Analysis of the efficacy and factors influencing the response of secondary hyperparathyroidism patients on hemodialysis to cinacalcet] [2010]
Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis. [2010.07]
[Secondary osteoporosis UPDATE. Therapy for bone-mineral disease in CKD-5D patients] [2010.05]
Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders. [2010.07]
Development and utility of a multi-dimensional grid to assess individual mineral metabolism control in hemodialysis patients: A potential aid for therapeutic decision making? [2010.04]
Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. [2010.05]
[Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy] [2010.04]
New therapies: calcimimetics, phosphate binders and vitamin D receptor activators. [2010.04]
Novel markers of left ventricular hypertrophy in uremia. [2010]
Interventions for bone disease in children with chronic kidney disease. [2010.01.20]
Pharmacology, efficacy and safety of oral phosphate binders. [2011.09.06]
[The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients]. [2011]
Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. [2011.09]
Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? [2011.05.13]
The phosphate binder equivalent dose. [2011.01]
Pharmacology of the phosphate binder, lanthanum carbonate. [2011]
Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. [2011.02.16]
Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study. [2011.01]
[Chronic kidney disease and atherosclerosis]. [2011.01]
Comparative effectiveness of calcium-containing phosphate binders in incident U.S. dialysis patients. [2011.01]
"Real-World" use of cinacalcet for managing SHPT in different European countries: analysis of data from the ECHO observational study. [2010.09]
Utilization of titanium oxide-like compound as an inorganic phosphate adsorbent for the control of serum phosphate level in chronic renal failure. [2010.08]
Does the choice of phosphate binder affect trace element levels in chronic kidney disease patients treated by regular haemodialysis? [2011.03]
[Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control]. [2010]
Effects of phosphate binders in moderate CKD. [2012]
Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia
in dialysis patients: a Canadian payer perspective. [2012]
Dissociation between progression of coronary artery calcification and endothelial
function in hemodialysis patients: a prospective pilot study. [2012]
Mortality in kidney disease patients treated with phosphate binders: a randomized
study. [2012]
|
